Staels, Bart

Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells

Marx, N., Duez, H., Fruchart, J.-C., & Staels, B. (2004) · Circulation Research

Peroxisome Proliferator-Activated ReceptorsCholesterol and Lipid Metabolism

Cited by 501

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 463

Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma

Guillaumond, F., Bidaut, G., Ouaissi, M., Servais, S., Gouirand, V., Olivares, O., Lac, S., Borge, L., Roques, J., Gayet, O., et al. (2015) · Proceedings of the National Academy of Sciences

Cancer, Lipids, and MetabolismPancreatic and Hepatic Oncology Research

Cited by 454

Kupffer Cells Promote Hepatic Steatosis Via Interleukin-1β–Dependent Suppression of Peroxisome Proliferator-Activated Receptor α Activity

Stienstra, R., Saudale, F., Duval, C., Keshtkar, S., Groener, J. E. M., van Rooijen, N., Staels, B., Kersten, S., & Müller, M. (2010) · Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 452

CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors

Chinetti, G., Gbaguidi, F. G., Griglio, S., Mallat, Z., Antonucci, M., Poulain, P., Chapman, J., Fruchart, J.-C., Tedgui, A., Najib-Fruchart, J., et al. (2000) · Circulation

Cholesterol and Lipid MetabolismAtherosclerosis and Cardiovascular Diseases

Cited by 428

Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis

Fruchart, J.-C., Duriez, P., & Staels, B. (1999) · Current Opinion in Lipidology

Peroxisome Proliferator-Activated ReceptorsCholesterol and Lipid Metabolism

Cited by 425

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: Hepatology

Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology

Liver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

Cited by 414

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.

Staels, B., Vu-Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., & Auwerx, J. (1995) · Journal of Clinical Investigation

Lipid metabolism and disordersPeroxisome Proliferator-Activated Receptors

Cited by 410

Human Atherosclerotic Plaque Alternative Macrophages Display Low Cholesterol Handling but High Phagocytosis Because of Distinct Activities of the PPARγ and LXRα Pathways

Chinetti-Gbaguidi, G., Baron, M., Bouhlel, M. A., Vanhoutte, J., Copin, C., Sebti, Y., Derudas, B., Mayi, T., Bories, G., Tailleux, A., et al. (2011) · Circulation Research

Atherosclerosis and Cardiovascular DiseasesCholesterol and Lipid Metabolism

Cited by 387

Myocardial Contractile Dysfunction Is Associated With Impaired Mitochondrial Function and Dynamics in Type 2 Diabetic but Not in Obese Patients

Montaigne, D., Marechal, X., Coisne, A., Debry, N., Modine, T., Fayad, G., Potelle, C., El Arid, J.-M., Mouton, S., Sebti, Y., et al. (2014) · Circulation

Mitochondrial Function and PathologyCardiovascular Function and Risk Factors

Cited by 322

Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbα antagonism: a single-centre propensity-matched cohort study and a randomised study

Montaigne, D., Marechal, X., Modine, T., Coisne, A., Mouton, S., Fayad, G., Ninni, S., Klein, C., Ortmans, S., Seunes, C., et al. (2018) · The Lancet

Cardiac and Coronary Surgery TechniquesCardiac Valve Diseases and Treatments

Cited by 315

Safety issues and prospects for future generations of PPAR modulators

RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids

Peroxisome Proliferator-Activated ReceptorsParaoxonase enzyme and polymorphisms

Cited by 309

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients

Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 260

Increased ABCA1 activity protects against atherosclerosis

Singaraja, R. R., Fievet, C., Castro, G., James, E. R., Hennuyer, N., Clee, S. M., Bissada, N., Choy, J. C., Fruchart, J.-C., McManus, B. M., et al. (2002) · Journal of Clinical Investigation

Cholesterol and Lipid MetabolismAtherosclerosis and Cardiovascular Diseases

Cited by 250

The circadian clock and liver function in health and disease

Mukherji, A., Bailey, S. M., Staels, B., & Baumert, T. F. (2019) · Journal of Hepatology

Circadian rhythm and melatoninLiver physiology and pathology

Cited by 246

PPAR-α–Null Mice Are Protected From High-Fat Diet–Induced Insulin Resistance

Guerre-Millo, M., Rouault, C., Poulain, P., André, J., Poitout, V., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Reach, G., & Staels, B. (2001) · Diabetes

Peroxisome Proliferator-Activated ReceptorsAdipokines, Inflammation, and Metabolic Diseases

Cited by 241

Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates

Shiri-Sverdlov, R., Wouters, K., Gorp, P. J. V., Gijbels, M. J., Noel, B., Buffat, L., Staels, B., Maeda, N., Bilsen, M. V., & Hofker, M. H. (2006) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 241

A Paradigm for Gene Regulation: Inflammation, NF-κB and PPAR

Vanden Berghe, W., Vermeulen, L., Delerive, P., De Bosscher, K., Staels, B., & Haegeman, G. (2003) · Advances in experimental medicine and biology

NF-κB Signaling PathwaysGenomics and Chromatin Dynamics

Cited by 222

Demonstration of a day-night rhythm in human skeletal muscle oxidative capacity

van Moorsel, D., Hansen, J., Havekes, B., Scheer, F. A. J. L., Jörgensen, J. A., Hoeks, J., Schrauwen-Hinderling, V. B., Duez, H., Lefebvre, P., Schaper, N. C., et al. (2016) · Molecular Metabolism

Circadian rhythm and melatoninAdipose Tissue and Metabolism

Cited by 218

Global Suppression of IL-6-induced Acute Phase Response Gene Expression after Chronic in Vivo Treatment with the Peroxisome Proliferator-activated Receptor-α Activator Fenofibrate

Gervois, P., Kleemann, R., Pilon, A., Percevault, F., Koenig, W., Staels, B., & Kooistra, T. (2004) · Journal of Biological Chemistry

Peroxisome Proliferator-Activated ReceptorsCytokine Signaling Pathways and Interactions

Cited by 212

Tau deletion promotes brain insulin resistance

Marciniak, E., Leboucher, A., Caron, E., Ahmed, T., Tailleux, A., Dumont, J., Issad, T., Gerhardt, E., Pagesy, P., Vileno, M., et al. (2017) · Journal of Experimental Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 205

Human ABCA1 BAC Transgenic Mice Show Increased High Density Lipoprotein Cholesterol and ApoAI-dependent Efflux Stimulated by an Internal Promoter Containing Liver X Receptor Response Elements in Intron 1

Singaraja, R. R., Bocher, V., James, E. R., Clee, S. M., Zhang, L.-H., Leavitt, B. R., Tan, B., Brooks-Wilson, A., Kwok, A., Bissada, N., et al. (2001) · Journal of Biological Chemistry

Cholesterol and Lipid MetabolismDrug Transport and Resistance Mechanisms

Cited by 194

Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction

Catry, E., Bindels, L. B., Tailleux, A., Lestavel, S., Neyrinck, A. M., Goossens, J.-F., Lobysheva, I., Plovier, H., Essaghir, A., Demoulin, J.-B., et al. (2018) · Gut

Microbial Metabolites in Food BiotechnologyGut microbiota and health

Cited by 194

A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA

Schattenberg, J. M., Pares, A., Kowdley, K. V., Heneghan, M. A., Caldwell, S., Pratt, D., Bonder, A., Hirschfield, G. M., Levy, C., Vierling, J., et al. (2021) · Journal of Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 191